Gene Therapy Discussion With Drs. Kaiser and Do at AAO

Peter K. Kaiser, MD, and Diana V. Do, MD, discuss first-time results of a bilateral dosing study of subretinal ABBV-RGX-314 for wet AMD.

By: Peter K. Kaiser, MD, Diana V. Do, MD

Retinal Physician October 25, 2024

Dr. Kaiser and Dr. Do discuss data presented at AAO showing that investigational gene therapy ABBV-RGX-314 (Regenxbio/AbbVie) is safe and effective when dosed in the fellow eye.

PentaVision

Retinal Physician

Gene Therapy Discussion With Drs. Kaiser and Do at AAO

Recommendations

What to Read Next

PentaVision

Retinal Physician

Gene Therapy Discussion With Drs. Kaiser and Do at AAO

Recommendations

What to Read Next

Upfront: Time for Fewer, But Stronger, Retina Societies

Anti-VEGF Therapy for Retinopathy of Prematurity

The Evolution of Clinical Trial Endpoints for Wet AMD

Results of Recent Trials of Duravyu for Wet AMD